Aptose Picks Up Hanmi’s MKI To Buoy Hematological Cancer Pipeline
$420m Deal Follows Positive Data
Analysts see Hanmi’s clinical-stage asset as fitting well into Aptose's pipeline and providing potential combination therapy benefits for hematological malignancies.
